These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

95 related items for PubMed ID: 8659199

  • 21. Atenolol versus amlodipine versus isosorbide-5-mononitrate on anginal symptoms in syndrome X.
    Lanza GA, Colonna G, Pasceri V, Maseri A.
    Am J Cardiol; 1999 Oct 01; 84(7):854-6, A8. PubMed ID: 10513787
    [Abstract] [Full Text] [Related]

  • 22. [Antihypertensive therapy in arterial occlusive disease].
    Diehm C.
    Vasa Suppl; 1991 Oct 01; 33():71-4. PubMed ID: 1686338
    [Abstract] [Full Text] [Related]

  • 23. Effects of buflomedil in a group of patients with chronic peripheral arterial diseases. Clinical and hemorheological evaluation.
    Mozzi E, Chiurazzi D, Spinola A, Annoni F, Germiniani R.
    J Int Med Res; 1985 Oct 01; 13(6):317-21. PubMed ID: 4076530
    [Abstract] [Full Text] [Related]

  • 24. Different effects of beta-1-adrenergic blocking agents with ISA or without ISA on peripheral blood flow.
    Karnik R, Valentin A, Slany J.
    Angiology; 1987 Apr 01; 38(4):296-303. PubMed ID: 2883920
    [Abstract] [Full Text] [Related]

  • 25. Antianginal and anti-ischemic efficacy of nicorandil in comparison with isosorbide-5-mononitrate and isosorbide dinitrate: results from two multicenter, double-blind, randomized studies with stable coronary heart disease patients.
    Döring G.
    J Cardiovasc Pharmacol; 1992 Apr 01; 20 Suppl 3():S74-81. PubMed ID: 1282180
    [Abstract] [Full Text] [Related]

  • 26. Patient self-reporting of compliance does not correspond with electronic monitoring: an evaluation using isosorbide dinitrate as a model drug.
    Straka RJ, Fish JT, Benson SR, Suh JT.
    Pharmacotherapy; 1997 Apr 01; 17(1):126-32. PubMed ID: 9017773
    [Abstract] [Full Text] [Related]

  • 27. Low-dose intermittent urokinase therapy in chronic symptomatic end-stage arterial disease--clinical relevance for patients with coronary artery disease or peripheral arterial occlusive disease.
    Leschke M, Schoebel FC, Strauer BE.
    Clin Hemorheol Microcirc; 1997 Apr 01; 17(1):59-66. PubMed ID: 9181759
    [Abstract] [Full Text] [Related]

  • 28. [Intravenous administration of PGE1: studies of the effectiveness and duration of the effect of various dosages based on flow measurements of the femoral artery in patients with healthy vessels and in stage IIb arterial occlusive disease].
    Scheffler P, Birkel L, Grub KR, de la Hamette D.
    Vasa Suppl; 1988 Apr 01; 23():126-9. PubMed ID: 3061035
    [No Abstract] [Full Text] [Related]

  • 29. [Use of selective long-acting beta-blocker with vasodilating activity celiprolol in patients with essential hypertension].
    Podzolkov VI, Mozharova LG.
    Kardiologiia; 2002 Apr 01; 42(10):22-6. PubMed ID: 12494052
    [Abstract] [Full Text] [Related]

  • 30. [Isosorbide-5-mononitrate in silent ischemia].
    Pichler M, Brandt D, Teubl H, Dorda W.
    Wien Klin Wochenschr; 1995 Apr 01; 107(13):390-5. PubMed ID: 7638969
    [Abstract] [Full Text] [Related]

  • 31. [New data on vasoactive drug. Patients with peripheral arterial occlusive disease walk twice as long].
    MMW Fortschr Med; 2002 May 23; 144(21):54. PubMed ID: 12134429
    [No Abstract] [Full Text] [Related]

  • 32. Celiprolol and atenolol in angina--effects on left ventricular function.
    Dargie H, McLenachan JM, Wilson JT.
    J Int Med Res; 1988 May 23; 16 Suppl 1():47A-51A. PubMed ID: 2906017
    [Abstract] [Full Text] [Related]

  • 33. Long-term reduction of peripheral resistance with celiprolol and effects on left ventricular mass.
    Trimarco B, Lembo G, DeLuca N, Ricciardelli B, Rosiello G, Volpe M, Orofino G, Condorelli M.
    J Int Med Res; 1988 May 23; 16 Suppl 1():62A-72A. PubMed ID: 2906018
    [Abstract] [Full Text] [Related]

  • 34. [Stress echocardiography--a new test for evaluating the anti-ischemic effect of medication].
    Leischik R, Adamczewski O, Pötter S, Erbel R, Lösse B.
    Z Kardiol; 1995 Aug 23; 84(8):621-32. PubMed ID: 7571769
    [Abstract] [Full Text] [Related]

  • 35. Attenuation of adenosine-induced myocardial perfusion heterogeneity by atenolol and other cardioselective beta-adrenoceptor blockers: a crossover myocardial perfusion imaging study.
    Reyes E, Stirrup J, Roughton M, D'Souza S, Underwood SR, Anagnostopoulos C.
    J Nucl Med; 2010 Jul 23; 51(7):1036-43. PubMed ID: 20554740
    [Abstract] [Full Text] [Related]

  • 36. Influence of changes in arterial blood pressure and peripheral arterial resistance on peak systolic velocity ratio.
    Kröger K, Massalha K, Rudofsky G.
    Vasa; 1998 Aug 23; 27(3):163-6. PubMed ID: 9747152
    [Abstract] [Full Text] [Related]

  • 37. [Long-term therapy of stress angina pectoris by a single daily administration of 120 mg isosorbide dinitrate in retard form. Comparison of monotherapy and combination therapy with atenolol and nifedipine].
    Blasini R, Brügmann U, Reiniger G, Rudolph W.
    Herz; 1985 Jun 23; 10(3):163-71. PubMed ID: 3926613
    [Abstract] [Full Text] [Related]

  • 38. Lack of effect of nitrates on exercise stress test results in patients with microvascular angina.
    Russo G, Di Franco A, Lamendola P, Tarzia P, Nerla R, Stazi A, Villano A, Sestito A, Lanza GA, Crea F.
    Cardiovasc Drugs Ther; 2013 Jun 23; 27(3):229-34. PubMed ID: 23338814
    [Abstract] [Full Text] [Related]

  • 39. [Comparative studies of the effect of a cardioselective and a noncardioselective beta-blocker on peripheral circulation in patients with arterial occlusive disease].
    Klieber M, Resch F.
    Wien Klin Wochenschr; 1986 Feb 07; 98(3):70-3. PubMed ID: 2938341
    [Abstract] [Full Text] [Related]

  • 40. Adding beta-2 agonism does not improve beta-1 blockade exercise responses in hypertensives.
    Rueckert PA, Slane PR, Hanson P.
    Med Sci Sports Exerc; 1994 Aug 07; 26(8):945-50. PubMed ID: 7968427
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.